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Background. Tobacco smoking cessation interventions in the oncology population are an important part of comprehensive
treatment plan. Objectives. To evaluate through a systematic review smoking cessation interventions and cessation rates in cancer
patients. Search Strategy. The literature was searched using Medline, EMBASE, and the Cochrane Library (inception to November
2010) by three independent review authors. Selection Criteria. Studies were included if tobacco smoking cessation interventions
were evaluated and patients were randomized to usual care or an intervention. The primary outcome measure was cessation
rates. Data Collection and Analysis. Two authors extracted data independently for each paper, with disagreements resolved by
consensus. Main Results. The systematic review found eight RCTs investigating smoking cessation interventions in the oncology
patient population. Pooled relative risks were calculated from two groups of RCTs of smoking cessation interventions based on
followup duration. In both groups, the pooled relative risk did not suggest a statistically signiﬁcant improvement in tobacco
cessation compared to usual care. Conclusions. Our review demonstrates that recent interventions in the last decade which are a
combination of non-pharmacological and pharmacological approaches yield a statistically signiﬁcant improvement in smoking
cessation rates compared to usual care.
1.Introduction
Smoking tobacco not only predisposes to the development
of disease, it increases disease severity and treatment failure
rates. For these reasons, tobacco cessation is a critical part
of the treatment of patients with cancer. Smoking cessation
particularly beneﬁts those patients who have smoking-
related cancers such as head and neck or lung cancer and
those who are diagnosed with curable disease [1].
Cigarette smoking and alcohol consumption are well-
established risk factors for developing squamous cell car-
cinoma of the head and neck. Furthermore, a number
of studies have revealed an association between tobacco
carcinogens and the molecular progression of squamous cell
carcinoma of the head and neck [2]. In countries with a high
prevalence of smoking, approximately 90% of diagnoses of
lung cancer are attributable to cigarette smoking. Further-
more, the increased incidence of lung cancer from smoking
isproportionaltothelengthandintensityofsmokinghistory
[3]. Smoking cessation before diagnosis reduces the risk of
developing a primary tumour of all major histological types
of lung carcinoma [3].
Prolonged tobacco smoking in cancer patients has many
adverse eﬀects during the oncology treatment plan as well.
Studies with head and neck and lung cancer patients demon-
strate that tobacco smoking reduces survival time [4]a n d
increases the risk of a recurrence or a second primary tumor
[4, 5]. Smoking also reduces the eﬃcacy of radiotherapy
in head and neck cancer patients, as smokers have a lower
rate of complete response and poorer 2-year survival rate
than nonsmokers and those who quit prior to treatment [6].
Tobaccosmokingalsoexacerbatesandprolongsradiotherapy
induced complications such as mucositis, dry mouth, loss of
taste,voice,impairedpulmonaryfunction,woundhealing,as
well as tissue and bone necrosis [4, 7]. Despite these adverse
health eﬀects, 23% to 35% of head and neck cancer patients
[5, 8–10] and 13% to 20% of lung cancer patients who
smoked prior to diagnosis continue to do so after diagnosis2 ISRN Oncology
[4]. Comorbid conditions such as depression, disease-related
anxiety, and alcohol abuse often make cessation challenging.
The diagnosis of cancer allows an opportunity for
patients to review and change their lifestyle habits [11, 12].
The health care setting is an ideal place to initiate cessation
interventions with smokers [13]. The earliest descriptions of
smoking cessation interventions in the health care setting
are described in a summary report by Schwartz [14]. Inter-
ventions may be hospital-based, community-based, or based
on individual counseling. Current smoking cessation inter-
ventionscanbeeitherpharmacological,nonpharmacological
or a combination of both. Examples of eﬀective approaches
include identifying tobacco use in patients, motivating them
to quit and supporting them to quit through brochures and
pamphlets, counseling, pharmacotherapy as well as regular
followup [2].
Despite the substantial beneﬁts of tobacco cessation in
cancer patients, there is still a relative paucity of data on
how to best achieve cessation in this population. The aim
of our study was to systematically review the literature
to summarize tobacco cessation interventions for cancer
patients and the associated smoking cessation rates as a
consequence of these interventions.
2. Methods
This systematic review was performed in accordance with
a predetermined protocol consisting of eligibility criteria,
a search strategy, outcomes, and statistical analysis. Our
primary aim was to perform a pooled analysis of smoking
cessation rates if appropriate.
2.1. Literature Search Strategy. The literature was searched
using OVID Medline (1950 through November 2010),
EMBASE (1980 to November 2010), and the Cochrane
Library (Cochrane Database of Systematic Reviews (2010
Issue 12). We used similar strategies to search all databases.
Relevant articles and abstracts were selected and reviewed,
and the reference lists from these sources and recent
review articles or meta-analyses were searched for additional
publications.
The literature search of the electronic databases com-
bined disease speciﬁc keywords (cancer, neoplasm, and
malignancy) with outcome speciﬁc keywords (tobacco cessa-
tion,smokingcessation,nicotinecessation,quitrates,patient
education, and patient intervention) for the following study
designsandpublicationtypes:retrospectivestudies,prospec-
tive cohort studies, randomized controlled trials (RCTs),
systematic reviews, and meta-analyses. The literature search
wasnotlimitedforstudydesignorpublicationdatetoensure
all relevant published articles were captured. All three study
authors performed a search using individual strategies.
2.2. Study Selection Criteria. The three authors reviewed
the studies identiﬁed by the search strategies for relevance.
Disagreements were resolved by consensus. Reasons for
exclusion were noted. Articles were included in the sys-
tematic review of the evidence if they were fully published
reports or abstracts of randomized controlled trials (RCTs)
evaluating a tobacco smoking cessation intervention versus
standard usual care in the adult smoking cancer population
(>18 years of age). To be included, trials had to report
cessation rates at followup.
Articles were excluded if they were published in a
language other than English, did not discuss a tobacco ces-
sation intervention, discussed nontobacco products without
separation of data, or were in the pediatric population.
2.3. Data Extraction. Relevant data was extracted from
fully published reports by two independent review authors
using prescribed tables. Any disagreement was resolved
with discussion and consensus. Primary authors of included
studies were contacted if further elaboration on data was
needed[1,13].Wherestudieswereduplicated,thelargerdata
set was used for the analysis [13, 18].
2.4. Statistical Analysis. Statistical calculations were per-
formed using the StatsDirect software (Chesire, UK). Given
that we analyzed prospectively gathered data from random-
ized trials, we calculated a pooled relative risk. The relative
risk was a ratio of the risk of tobacco cessation in the
intervention group versus the risk of tobacco cessation in the
control group. The relative risks were calculated where data
was available by intention-to-treat analysis.
Pooled relative risks were calculated using the Rothman-
BoicetypeofMantel-Haenszelmethodassumingﬁxedeﬀects
[15]. The random-eﬀects model of pooled relative risks was
calculated using the DerSimonian-Laird method [19]. The
decision to use either a random eﬀects model or a ﬁxed
eﬀects model was based on calculation of heterogeneity of
the data using an I2 calculation. Where heterogeneity of the
data was large, a random eﬀects model was used. Conﬁdence
intervals of the pooled relative risk were calculated using the
Greenland-Robin variance formula [16].
3. Results
3.1. Literature Search. Eight studies [1, 4, 11, 13, 17, 20–22]
were narrowed down through the search (Figure 1). All the
studiesidentiﬁedwereRCTsintheadultsmokingpopulation
which described a tobacco smoking cessation intervention
and smoking cessation rates.
3.2. Trial Characteristics. All published studies (Table 1)
were RCTs, which were either single center [11, 13, 17,
21, 22]o rm u l t i c e n t e r[ 1, 4, 20]. There were a total of
1304 patients included. The included studies did not show
signiﬁcant diﬀerences in baseline characteristics of mean
age and gender distribution except in studies that included
o n l yh e a da n dn e c kp a t i e n t s[ 11, 13]( Table 1). Smoking
cessation interventions were delivered by the health care
team. Interventions were nonpharmacological (cognitive
behavioral therapy, self-help material, education modules,
motivational interviewing), or pharmacological (nicotine
replacement therapy or bupropion) (Table 2). All studies
evaluated tobacco smoking.ISRN Oncology 3
1728 
Potentially relevant studies identiﬁed
abstracts reviewed for inclusion criteria
68 
Studies retrieved through consensus 
further assessed for inclusion criteria 
8
Included
studies met all inclusion criteria 
1660 excluded 
60 excluded
Figure 1: Flow diagram outlining our search strategy.
3.3. Tobacco Cessation Rates and Followup. All the studies
used self-reported rates of tobacco cessation. In addition,
some studies used biochemical veriﬁcation as well for smok-
ingcessation.Twoofthestudiesusedbreathtestingofcarbon
monoxide (CO) [11, 21], two studies used urine cotinine
levels [1, 11] and two studies used saliva cotinine levels [13,
17] where possible to conﬁrm self-reported rates (Table 2).
Cessation rates depending on randomization varied for
each study at diﬀerent followup times (Table 3). The studies
were evaluated in two groups, one group with a shorter
followup time, mean of 5 weeks [13, 17, 22] and the other
group had a longer followup time of at least 6 months [1, 4,
11, 20]. In the second group, pooled rates were calculated
from the 6 month abstinence rates in all studies except in
one study which did not report a 6 month rate but only a
12 month rate [1]. Schnoll et al’.s study [21]w a se x c l u d e d
from the longer followup group and analysis due to a purely
pharmacological intervention compared to the other studies
in the other group which were combination interventions.
For the purpose of pooling data, only self-reported data
was pooled. When we examined the shorter followup group,
the pooled relative risk was calculated to be 1.16 (95% CI =
0.80to1.76)intheshortfollowupgroup(Figure 2).Thiswas
calculated using the ﬁxed eﬀects model. The longer followup
group had a pooled relative risk of 1.19 (95% CI = 0.78
to 1.78) (Figure 3). The random eﬀects model was used to
calculate this pooled relative risk. When the oldest study
was excluded form this series the result changed dramatically
[1]. The pooled relative risk of the three most recent studies
shows a result that is much more positive, with the relative
risk achieving statistical signiﬁcance. This pooled rate was
calculated to be 1.42 (95% CI, 1.05 to 1.94).
4. Discussion
The systematic review identiﬁed eight studies which met
inclusion criteria. We used a broad search strategy with
Relative risk meta-analysis plot (random eﬀects)
0.2 0.5 1 2 5 10
Schnoll et al 2005 0.93 (0.6, 1.42)
Griebel et al. 1998 1.5 (0.33, 6.94)
Wewers et al. 1994 1.29 (0.68, 2.49)
Combined (random) 1.04 (0.74, 1.47)
Relative risk (95% conﬁdence interval)
l.
Figure 2: Meta-analysis plot looking at relative risk in the shorter
followup group.
Relative risk meta-analysis plot (random eﬀects)
0.5 1 2 5
Gritz et al. 1993 0.81 (0.59, 1.09)
Wakeﬁeld et 1.7 (0.76, 3.9)
Schnoll et al. 2003 1.19 (0.73, 1.95)
Duﬀy et al. 2006 1.64 (0.92, 2.99)
Combined (random) 1.18 (0.78, 1.78)
Relative risk (95% conﬁdence interval)
al. 2004
Figure 3:Evaluatingtherelativeriskthroughrandomeﬀectsforthe
longer followup group.
multiple reviewers. When necessary, authors were contacted
to provide additional data to ensure an accurate data set.
The identiﬁed papers were methodologically sound with
prospectively gathered data, randomized study populations,
and suitable control groups.
All eight studies had slightly diﬀerent smoking cessation
treatment plans. Only one study [21]l o o k e da tap u r e l y
pharmacological approach to tobacco cessation while three
studies had only a nonpharmacological approach [1, 13, 17].
Four studies [4, 11, 20, 22] had a combination approach of
nicotine replacement therapy, counseling and/or cognitive
behavioral study. Duﬀy et al. [20] looked at the combination
ofcognitive behavioral therapy in addition to bupropion and
nicotine replacement therapy. Comparison of the conﬁdence
intervals of the calculated relative risks of the studies
does not demonstrate a signiﬁcant diﬀerence in tobacco
smoking cessation rates between any of the diﬀerent types
of intervention.
Similar to other systematic reviews, our analysis com-
prised of a relatively high heterogeneity of treatments and
patient groups. This type of heterogeneity is common and
should be incorporated into systematic reviews [19]. We4 ISRN Oncology
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Table 3: Summary of tobacco smoking cessation rates.
Study Intervention group Usual care group
Total no. of pts No. patients who ceased smoking (%) Total no. of pts. No. of pts who ceased smoking (%)
Long followup (mean 6 mo.)
Duﬀy et al. 2006 [20]6 2 2 3 5 3 1 2
Schnoll et al. 2003 [4] 215 30 214 25
Wakeﬁeld et al. 2004 [11]7 4 1 4 6 3 7
Gritz et al. 1993 [1]5 0 2 9 4 6 3 3
Schnoll et al. 2010 [21] 114 21 132 23
Short followup (5-6 weeks)
Wewers et al. 1994 [13]1 4 9 1 6 8
Griebel et al. 1998 [17]1 8 3 1 8 2
Schnoll et al. 2005 [22]5 2 2 2 5 7 2 6
incorporated this heterogeneity when present using random
eﬀects models.
The studies were divided into two groups—short fol-
lowup time (mean 5 weeks) and longer followup time (6
months). While comparing the pooled relative risks of the
two groups, it does not demonstrate a signiﬁcant diﬀerence
in the cessation rates despite the fact that a longer followup
time would tend to represent better cessation rates. However,
considering the shorter followup times, it is diﬃcult to state
whether at 6 months, this group would continue to have the
same cessation rates.
When we examined the longer followup group, four
studies were included [1, 4, 11, 20]. The original study was
performedintheearly1990[1].Thisstudyexaminedagroup
of 186 head and neck cancer patients and utilized a non-
pharmacological counseling-based approach. If this original
study is excluded from the analysis, this long-term followup
groupdoesappeartoyieldastatisticallysigniﬁcanteﬀectdue
toamulti-modal cessationintervention. Notably,theseother
three studies [4, 11, 20] were performed in the most recent
decade and examined 705 patients with diverse oncologic
diagnoses. Furthermore, these three studies all included a
pharmacological approach in addition to nonpharmacolog-
ical intervention. These diﬀerences may account for the rea-
sonthatthepoolingmostrecentstudiesreachesastatistically
signiﬁcant eﬀect for smoking cessation intervention.
In addition, the setting in which the cessation methods
were oﬀered are also diﬀerent. Some studies counseled
patients on smoking cessation during a postoperative hos-
pital admission, while other interventions were provided in
the clinics. Comparing the cessation rates of the individual
studies does not demonstrate a signiﬁcant diﬀerence in the
cessation patterns based on setting.
Not all studies performed biochemical veriﬁcation of
tobacco cessation. Consequently, our pooled rates were
calculated for self-reported tobacco cessation. It is unlikely
the self-reported rates would bias our review towards a
negative result.
When all studies are analyzed in the short and long-
term, there was no statistical to a tobacco smoking cessation
intervention in addition to usual care. However, when exam-
ining the eﬀect of a multifaceted approach (pharmacological
and nonpharmacological) to smoking cessation, the analysis
suggested a more positive result.
5. Conclusion
There are few RCTs evaluating smoking cessation inter-
ventions. Our review does not demonstrate a signiﬁcant
diﬀerence in tobacco smoking cessation rates through these
interventions. The data does, however, suggest that the com-
bination of both pharmacological and nonpharmacological
approaches may be more successful at achieving tobacco
cessation.
Tobacco cessation is a formidable challenge in this com-
plex patient population. Collaboration within the health-
careteamisparamountinimplementingasmokingcessation
intervention. The signiﬁcant beneﬁts of tobacco cessation
demand the oncology team continue to explore and inves-
tigate novel and known methods to help patients become
tobacco-free.
Abbreviations
RCT: Randomized control trial.
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